The United States Department of Health and Human Services has placed an order to fill 7.6 million doses of unadjuvanted H1N1 pandemic vaccine from GSK, which will contribute to the approximately 250 million doses secured by the US government. The vaccine will be produced in multi-dose vials from bulk vaccine manufactured at GSK's facility in Quebec, Canada. GSK expects to begin shipping vaccine in December and to provide all 7.6 million doses by the end of the year.
Globally, GSK manufactures both adjuvanted and unadjuvanted vaccines to protect against pandemic H1N1 influenza. GSK will supply a vaccine containing a standard dose (15 ug) of inactive influenza virus antigens without an adjuvant for use in the United States. Clinical trials for both GSK's adjuvanted and unadjuvanted vaccines are ongoing in North America, Europe and Japan.
Further information on GSK's development of vaccines to protect against pandemic H1N1 influenza, including explanation of the vaccine development process is available on: www.gsk.com/media/pandemic-flu.htm
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.